Literature DB >> 2548699

The establishment of Epstein-Barr virus nuclear antigen-positive (SP-50B) and Epstein-Barr virus nuclear antigen-negative (SP-53) cell lines with t(11;14)(q13;q32) chromosome abnormality from an intermediate lymphocytic lymphoma.

M Daibata1, I Kubonishi, T Eguchi, S Yano, Y Ohtsuki, I Miyoshi.   

Abstract

Two lymphoma cell lines, SP-50B and SP-53, were established from peripheral blood of a 58-year-old woman with leukemic conversion of intermediate lymphocytic lymphoma. These cell lines grew in suspension with or without forming clumps of cells. SP-50B was morphologically similar to the common Epstein-Barr (EB) virus-transformed lymphoblastoid cell lines and was positive for EB virus nuclear antigen (EBNA), whereas SP-53 closely resembled the patient's lymphoma cells and was negative for EBNA. Both cell lines expressed the same phenotypic markers as original lymphoma cells (CpIg+, SmIg+, OKIa1+, Leu12+) and possessed t(11;14)(q13;q32) chromosome translocation. These results indicate that although morphologically different, SP-50B and SP-53 were both derived from patient's lymphoma cells. The long-term cultivation of EBNA-positive and EBNA-negative B-cell lymphoma lines from a single donor has not been previously reported. These cell lines would provide useful tools for studying the oncogenic role of EB virus and bcl-1 oncogene that is located on chromosome 11q13.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548699     DOI: 10.1002/1097-0142(19890915)64:6<1248::aid-cncr2820640614>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  A new monoclonal antibody to human subcapsular thymic epithelial cells.

Authors:  T Takeuchi; I Kubonishi; Y Ohtsuki; I Miyoshi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Differential tumorigenicity between Epstein-Barr virus genome-positive and genome-negative cell lines with t(11;14)(q13;q32) derived from mantle cell lymphoma.

Authors:  M Daibata; I Kubonishi; I Miyoshi
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

3.  Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.

Authors:  L M Saleh; W Wang; S E M Herman; N S Saba; V Anastas; E Barber; M Corrigan-Cummins; M Farooqui; C Sun; S M Sarasua; Z Zhao; N K Abousamra; O Elbaz; H A Abdelghaffar; A Wiestner; K R Calvo
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.